Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer

NCT ID: NCT01591590

Last Updated: 2021-10-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2021-09-25

Brief Summary

The purpose of this study is to assess whether in a population of patients with advanced colorectal cancer for which no known effective therapy is available, measuring the spontaneous evolution of tumoral metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion MRI are able to measure it.

Detailed Description

Natural history of tumors is a poorly studied subject, the clinical evidence of some tumors aggressiveness as opposed to some other's indolent behavior has never been formally assessed in daily practice or in clinical studies and remains largely unpredictable. The patient's populations are in fact a mix between different tumoral phenotypes that while carrying the same apparent disease evolve with different outcomes.

We hypothesize that,in a population of patients with advanced colorectal cancer for which no known effective therapy is available, measuring the spontaneous evolution of tumoral metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion MRI are able to measure it.

If the hypothesis is verified, this finding could:

• Allow to define therapeutic strategies according to the tumoral metabolic progression index.
• Limit the need for randomization in the early drug development phases as each patient could be considered as his own control.
• To stratify patients according to their baseline metabolic growth rate in randomized controlled trials with overall survival as an endpoint.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

All Patients

This is an Interventional, Non Therapeutic arm

Group Type: EXPERIMENTAL

FDG PET-CT

Intervention Type: OTHER

All patients will undergo FDG PET-CT at inclusion and 2 weeks after

Diffusion MRI

Intervention Type: OTHER

All patients will undergo Diffusion MRI at inclusion and 2 weeks later

Blood samples (plasma preparation and CTC)

Intervention Type: OTHER

Interventions

FDG PET-CT

All patients will undergo FDG PET-CT at inclusion and 2 weeks after

Intervention Type: OTHER

Diffusion MRI

All patients will undergo Diffusion MRI at inclusion and 2 weeks later

Intervention Type: OTHER

Blood samples (plasma preparation and CTC)

Intervention Type: OTHER

Other Intervention Names

Metabolic Investigation; Metabolic Investigation

Eligibility Criteria

Inclusion Criteria

• Participants must have histologically confirmed colorectal cancer that is metastatic or unresectable and for which standard treatments do not exist or are no longer effective.
• The tumor should be refractory to all standard chemotherapy agents (fluoropyrimidines, irinotecan, and oxaliplatin) and anti-EGFR monoclonal antibodies in case of wild type Kras (cetuximab or panitumumab) administered before study entry. Prior treatment with bevacizumab, regorafenib and/or aflibercept is allowed but not mandatory
• Participants should be candidate for a Phase I study
• Age equal or over 18 years.
• Life expectancy of greater than 12 weeks.
• ECOG performance status ≤ 1.
• Participants must have normal organ and marrow function as defined below:

Total bilirubin within 2 × normal institutional upper limits AST/ALT/Alk Phosphatase levels < 5 × normal institutional upper limits Creatinine within 2 × normal institutional upper limits or creatinine clearance > 35mL/min

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry during the assessment. For women of childbearing potential a pregnancy test (urinary or serum) must be performed within 7 days prior to inclusion and it must be negative. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately within one month.
• Signed written informed consent obtained prior to any study specific screening procedures).

Exclusion Criteria

Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study:

• Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
• Participants who have had a major surgery or radiotherapy within 4 weeks prior to entering the study.
• Patients receiving any experimental agents during the assessment time period.
• Patients with uncontrolled brain metastases.
• Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months.
• Participants who have had a major surgery or radiotherapy within 4 weeks prior to entering the study
• Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or any significant disease which, in the investigator's opinion, would exclude the patient from the study.
• Pregnancy or breastfeeding before the FDG PET-CT scan examinations
• Uncontrolled Diabetes.
• Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
• Contra-indications to the use of MRI: cardiac stimulator, implanted cardiac wires, any implanted electronic devices, intra-ocular metallic foreign bodies.
• Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jules Bordet Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Amélie Deleporte, MD

Role: PRINCIPAL_INVESTIGATOR

Jules Bordet Institute , Universite Libre De Bruxelles

Locations

Jules Bordet Institute

Brussels, , Belgium

Countries

Belgium

References

Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, Hendlisz A. Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study. BMC Cancer. 2014 May 30;14:385. doi: 10.1186/1471-2407-14-385.

Reference Type: DERIVED

PMID: 24885112 (View on PubMed)

Related Links

http://www.bordet.be/

Jules Bordet Institute

Other Identifiers

2011-006280-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CORIOLAN

Identifier Type: -

Identifier Source: org_study_id